TITLE

US Okays More Potent HIV Drug Formulation

PUB. DATE
February 2005
SOURCE
Clinical Infectious Diseases;2/15/2005, Vol. 40 Issue 4, preceding p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article reports that the U.S. Food and Drug Administration has granted approval to a more potent formulation of Roche AG's HIV drug invirase, meaning that patients will not need to take as many of the pills.
ACCESSION #
15865421

 

Related Articles

  • Roche: expanding options, increasing sales.  // PharmaWatch: Monthly Review;Jul2005, Vol. 4 Issue 7, p29 

    The article reports on the approval granted by the Food and Drug Administration to Roche Pharmaceuticals' Pegasys in the U.S. The company's leading interferon, Pegasys, has been approved for the treatment of chronic hepatitis B virus (HBV). Already widely used for hepatitis C therapy, this...

  • Roche: Invirase pill burden halved.  // PharmaWatch: Monthly Review;August 2004, Vol. 3 Issue 8, p30 

    Roche Inc. has submitted a New Drug Application to the U.S Food and Drug Administration (FDA) for a 500mg formulation of Invirase. Invirase is a key component of many combination antiretroviral regimes for the treatment of HIV, and the new 500mg formulation would significantly reduce the pill...

  • What T-DM1 Means for Roche And Biotechs on the AA Path. Morrison, Trista // BioWorld Insight;9/27/2010, Vol. 18 Issue 39, p1 

    The article reports on the issue regarding the ruling of the U.S. Food and Drug Administration (FDA). It states that Roche's AG's bevacizumab and ImmunoGen Inc.'s breast cancer drug trastuzumab-DMI did not qualify for review under the accelerated approval pathway. It notes that FDA rejected the...

  • FDA actions in brief.  // Formulary;Sep2007, Vol. 42 Issue 9, p523 

    The article offers news briefs related to drugs approved by the U.S. Food and Drug Administration. Two lower doses of oseltamivir with brand name Tamiflu from Roche Pharmaceuticals were for the treatment and prevention of influenza types A and B. A dosage strength of carbidopa, levodopa and...

  • Genentech wins FDA approval for rheumatoid arthritis drug.  // PharmaWatch: Biotechnology;Feb2010, Vol. 9 Issue 2, p12 

    The article reports on the approval of Food and Drug Administration of Genentech Inc.'s Actemra that is use to treat patients with active rheumatoid arthritis (RA) in the U.S. Actemra is the first interleukin-6 receptor inhibiting monoclonal antibody that can either be used alone or with...

  • An FDA advisory.  // Medical Marketing & Media;Dec2005, Vol. 40 Issue 12, p11 

    The article reports that the U.S. Food and Drug Administration has determined that Roche Pharmaceuticals' anti-flu drug Tamiflu is safe after finding no direct link between the drug and the deaths of 12 Japanese children who had taken it.

  • Tarceva approved for pancreatic cancer.  // Drug Topics;11/21/2005, Vol. 149 Issue 22, p8 

    This article reports that Roche Inc.'s Tarceva will already benefit patients with advanced pancreatic cancer following its Food and Drug Administration approval in the U.S.

  • FDA Panel Backs Roche Arthritis Drug.  // Bioworld Week;8/4/2008, Vol. 16 Issue 31, p4 

    The article reports on the move of the U.S. Food and Drug Administration panel of advisers in supporting the approval of the arthritis drug Actemra or tocilizumab by Roche Holding AG. It stresses that although the potential risks of cardiovascular and gastrointestinal events of Actemra weighed...

  • Roche's IPF drug gets regulatory nod.  // BioSpectrum;Nov2014, Vol. 12 Issue 11, p12 

    The article reports on the announcement from global health-care company F. Hoffmann-La Roche Ltd. saying that the U.S. Food and Drug Administration (US FDA) approved the company's Esbriet drug used in treating idiopathic pulmonary fibrosis (IPF).

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics